Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate;: Prevenar(TM)) in Korean infants:: Differences that are found in Asian children

被引：18

作者：

Kim, Nam-Hee

Lee, Jina

Lee, Sang Jeong

Le, Hyunju

Kim, Kyung-Hyo

Park, Su-Eun

Lee, Hoan-Jong

机构：

[1] Seoul Natl Univ Childrens Hosp, Dept Pediat, Seoul 110744, South Korea

[2] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea

[3] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Pediat, Goyang Si, South Korea

[4] Seoul Natl Univ, Boramae Hosp, Dept Pediat, Seoul, South Korea

[5] Ewha Womans Univ, Sch Med, Dept Pediat, Seoul, South Korea

[6] Pusan Natl Univ, Coll Med, Dept Pediat, Pusan, South Korea

来源：

VACCINE | 2007年 / 25卷 / 45期

关键词：

pneumococcal conjugate vaccine; reduced dose vaccination; ethnic groups;

D O I：

10.1016/j.vaccine.2007.08.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study was conducted to determine the immunogenicity and safety of a 7-valent CRM197 protein conjugated pneumococcal vaccine (PCV7) in Korean infants immunized at 2, 4 and 6 months. A total of 202 infants were enrolled and 146 and 141 infants were, respectively, included in post-2nd dose and post-3rd dose immunogenicity evaluations conducted on a per protocol basis. After two and three PCV7 vaccinations, 63.0-98.0 and 97.2-100% of infants achieved an antibody level of >= 0.35 mu g/mL, respectively, with a lowest against serotype 6B. No vaccination-related serious adverse reactions were observed. Thus, PCV7 appears safe and highly immunogenic in Korean infants, and adopting two doses for a primary series could be a feasible option for facilitating vaccine coverage rate. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：7858 / 7865

页数：8

共 32 条

[1] Streptococcus pneumonia capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory [J].